Table 5.
Parameters of OCT according to choroidal neovascularization (CNV) group in eyes with type 1 CNV.
| Group A | Group B | Group C | p-Value | |
|---|---|---|---|---|
| No. of eyes | 10 | 15 | 9 | |
| Mean age | 77.3 ± 7.60 | 71.6 ± 10.2 | 72.9 ± 9.3 | 0.329 † |
| Sex (female, %) | 6 (60) | 3 (30) | 4 (44.5) | 0.158 † |
| BCVA, logMAR | 0.66 ± 0.51 | 0.40 ± 0.29 | 0.53 ± 0.52 | 0.364 † |
| IOP, mmHg | 13.2 ± 2.8 | 15.1 ± 2.7 | 15.8 ± 4.3 | 0.195 * |
| No. of treatment naive eyes | 0 | 2 | 0 | 0.492 † |
| No. of intravitreal injection | 5.0 ± 2.7 | 7.1 ± 5.1 | 6.3 ± 4.9 | 0.541 ‡ |
| Disease duration, months | 15.6 ± 10.4 | 21.6 ± 15.6 | 19.8 ± 15.2 | 0.597 * |
| PED max height, μm | 1193.3 ± 214.6 | 144.9 ± 122.9 | 181.1 ± 120.6 | 0.72 ‡ |
| PED max width, μm | 2729.2 ± 1473.2 | 2577.2 ± 1386.1 | 1990.9 ± 1380.6 | 0.489 ‡ |
| Choroidal thickness, μm | 205.1 ± 73.9 | 239.5 ± 111.0 | 251.2 ± 114.2 | 0.588 ‡ |
| Center fovea thickness, μm | 214.6 ± 67.3 | 264.8 ± 140.1 | 274.7 ± 128.9 | 0.491 ‡ |
| CNV area, mm2 | 2.31 ± 1.27 | 1.70 ± 1.27 | - | 0.249 |
| SRF existence, number of eyes | 3 | 7 | 4 | 0.747 † |
| SRF height in eyes with SRF, μm | 139.3 ± 57.7 | 79.7 ± 43.0 | 106.0 ± 56.5 | 0.532 ‡ |
BCVA: best-corrected visual acuity; IOP: intraocular pressure; PED: pigment epithelial detachment (serous or vascularized); CNV: choroidal neovascularization; SRF: subretinal fluid. * One-way ANOVA, † Fisher’s exact test; ‡ Kruskal-Wallis test.